CHU Caen Normandie improves cardiac and renal care for patients

The CHU Caen Normandie is the winner for two prestigious Clinical Research Hospital Projects this year.

These PHRCs support promising research projects carried out by health professionals from the cardiology and nephrology departments of the CHU, aimed at improving the medical management of two major issues: the optimal duration of medical treatment after cardiac surgery to reduce the risk of bleeding in elderly patients, and prevention by administering a new anticoagulant which could offer better protection against blood clots in patients with kidney failure.

These medical advances aim to improve patient care and offer better treatment prospects.

“SOLOPCI trial” project

Led by Dr Vincent Roule , Pr Farzin Beygui and Pr Paul-Ursmar Milliez from the cardiology department of CHU Caen Normandie, this project aims to determine the ideal duration of medical treatment after coronary heart surgery. The objective is to reduce the risk of bleeding while maintaining effective protection against the risk of thrombosis, in particular myocardial infarction and/or stroke, in a population of elderly patients. The researchers hypothesize that the very short antiplatelet treatment strategy could further reduce bleeding without compromising protection against thrombotic events, which could revolutionize medical practices by becoming the default strategy in this growing patient population and too little studied.

“APIDP2 trial” project

Led by Dr Maxence Ficheux and Pr Thierry Lobbedez from the nephrology department of CHU Caen Normandie, this project focuses on the treatment of atrial fibrillation in patients on peritoneal dialysis. Patients with kidney failure on peritoneal dialysis are often excluded from clinical trials, making determining an effective treatment even more difficult. The study aims to evaluate a new anticoagulant that may offer better protection against blood clots while reducing the risk of bleeding in this specific population.

If this study confirms the hypothesis formulated, this new anticoagulant could offer a significant advantage in terms of reduced bleeding compared to standard treatment, which would be a major advance in the treatment of this specific population.

CHU Caen Normandie's commitment to translational scientific research

These two PHRCs testify to the CHU Caen Normandie's commitment to scientific research , aimed at implementing cutting-edge scientific knowledge to improve patient care and quality of life. The results of these studies could have a significant impact on clinical practices and pave the way for new therapeutic approaches.

The CHU Caen Normandie will continue to invest in research and innovation to offer leading medical advances to its patients, with a focus on crucial health issues such as those addressed in the Solopici and APIDP2 projects.